

Measure ID	Measure Description	Developer	NQF #
Coronary Artery Disease (CAD) Measure Set			
Cardio 33	Complete Lipid Profile: Percentage of patient aged ≥ 18 years with a diagnosis of CAD who received at least one lipid profile with all four numerical component values documented within a 12-month period	ACCF/AHA/PCPI	
Cardio 36	Statin Therapy: Percentage of aged ≥ 18 years with a diagnosis of CAD with a prescription of a statin	ACCF	
Cardio 102	Symptom and Activity Management: Percentage of patients aged ≥ 18 years with a diagnosis of CAD seen within a 12-month period for whom there are documented results of an evaluation of level of activity and an evaluation of presence or absence of angina symptoms in the medical record	ACCF/AHA/PCPI	
Cardio 103	Symptom Management: Percentage of patients aged ≥ 18 years with a diagnosis of CAD seen within a 12-month period and with results of an evaluation of level of activity, and with an evaluation of presence or absence of anginal symptoms, with appropriate management of anginal symptoms (evaluation of level of activity and symptoms includes no report of anginal symptoms, OR evaluation of level of activity and symptoms includes report of anginal symptoms and a plan of care is documented to achieve control of anginal symptoms)	ACCF/AHA/PCPI	
Cardio 105	Antiplatelet Therapy: Percentage of patients aged ≥ 18 years with a diagnosis of CAD seen within a 12-month period who were prescribed aspirin or clopidogrel	AHA	0067
Cardio 106	Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%): Percentage of patients aged ≥ 18 years with a diagnosis of CAD seen within a 12-month period who also have prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy	ACCF	0070
Cardio 107	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – Diabetes or Left Ventricular Systolic Dysfunction (LVEF <40%): Percentage of patients aged 18 years and older with a diagnosis of CAD seen within a 12-month period who also have diabetes or a current or prior LVEF <40% who were prescribed ACE inhibitor or ARB therapy	AHA	0066
Cardio 108	Cardiac Rehabilitation (CR) Patient Referral from an Outpatient Setting: Percentage of patients evaluated in an outpatient setting who within the previous 12 months have experienced an acute myocardial infarction, coronary artery bypass graft surgery, PCI, cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina and have not already participated in an early outpatient CR or secondary prevention program for the qualifying event/diagnosis and are referred to such a program	AHA	0643
Cardio 109	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Percentage of Patients 18-75 with a diagnosis CAD who were offered moderate-to-high intensity statin	ACCF/AHA/PCPI	

Measure ID	Measure Description	Developer	NQF #
Heart Failure (HF) Measure Set			
Cardio 14	Advance Care Plan: Percentage of patients aged 65 years and older with a diagnosis of HF who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan	ACCF	
Cardio 140	LVEF Assessment: Percentage of patients aged ≥18 years with a diagnosis of HF for whom the quantitative or qualitative results of a recent or prior (any time in the past) left ventricular ejection fraction assessment is documented within a 12-month period	ACCF	0079
Cardio 141	Symptom and Activity Assessment: Percentage of patient visits for those patients aged ≥18 years old with a diagnosis of HF with quantitative results of an evaluation of both current level of activity and clinical symptoms documented	ACCF/AHA/PCPI	
Cardio 142	Symptom Management: Percentage of patient visits for those patients aged ≥18 years old with a diagnosis of HF and with quantitative results of an evaluation of both level of activity and clinical symptoms documented in which patient symptoms have improved or remained consistent with treatment goals since last assessment OR patient symptoms have demonstrated clinically important deterioration since last assessment with a documented plan of care	ACCF/AHA/PCPI	
Cardio 143	Patient Self Care Education: Percentage of patients aged ≥18 years with a diagnosis of HF who were provided with self-care education on ≥3 elements of education during ≥1 visit within a 12-month period	ACCF	
Cardio 144	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction LVSD: Percentage of patients aged ≥18 y with a diagnosis of HF with a current or prior LVEF of <40% who were prescribed beta-blocker therapy with bisoprolol, carvedilol, or sustained release metoprolol succinate either within a 12-month period when seen in the outpatient setting or at hospital discharge	ACCF	0083
Cardio 145	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) therapy for Left Ventricular Systolic Dysfunction (LVSD): Percentage of patients aged 18 years and older with a diagnosis of HF with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge	ACCF	0081
Cardio 151	Hydralazine and Isosorbide Dinitrate Therapy for African Americans with Left Ventricular Systolic Dysfunction: Percentage of patients age ≥18 y with a diagnosis of heart failure and a current or prior ejection fraction ≤40% who are self-identified as Black or African American and receiving ACE inhibitor, ARB, or ARNI therapy and beta-blocker therapy who were prescribed a combination of hydralazine and isosorbide dinitrate.	ACCF	

Measure ID	Measure Description	Developer	NQF #
Hypertension Measure Set			
Cardio 172	Measure Name Stage 2 High Blood Pressure Control Systolic Blood Pressure less than 140 mm Hg: Percentage of patients aged 18 to 85 years, with a diagnosis of Stage 2 High Blood Pressure (HBP) (as defined by ACC/AHA) whose most recent systolic blood pressure (SBP) reading < 140 mm Hg during the measurement period	ACCF/AHA	
Cardio 173	Stage 1 High Blood Pressure Control Systolic Blood Pressure less than 130 mm Hg: Percentage of patients aged 18 to 85 years, with a diagnosis of Stage 1 High Blood Pressure (HBP) (as defined by ACC/AHA) whose most recent systolic blood pressure (SBP) reading < 130 mm Hg during the measurement period	ACCF/AHA	
Atrial Fibrillation (AF) and Atrial Flutter Measure Set			
Cardio 160	CHA₂DS₂-VASC Risk Score Documented: Percentage of patients age ≥18 years with nonvalvular AF or atrial flutter for whom a CHA ₂ DS ₂ -VASC risk score is documented	ACCF/AHA/PCPI	
Cardio 161	Atrial Fibrillation/Atrial Flutter: Anticoagulation Prescribed: Percentage of patients, age ≥18 years, who were prescribed warfarin or another FDA- approved anticoagulant drug for the prevention of thromboembolism	ACCF/AHA/PCPI	
Cardio 171	Atrial Fibrillation/Atrial Flutter: Beta Blocker Therapy: Percentage of patients aged 18 years and older, with a diagnosis of Atrial Fibrillation or Atrial Flutter AND with an LVEF ≤ 40 who were prescribed a beta blocker during the measurement period	ACCF/AHA	
Peripheral Artery Disease (PAD) Measure Set			
Cardio 170	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Percentage of Patients 18-75 years of age with a diagnosis of PAD who were offered	ACCF	
Preventive Care Measure Set			
Cardio 104	Tobacco Use: Screening and Cessation Intervention: Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months and who received cessation counseling intervention if identified as a tobacco user	NCQA	0028

Cardiology Registry participants include clinicians in cardiology, family medicine, and internal medicine in ambulatory care settings. Providers must be able to report at least 10 of the measures listed above to be eligible for participation in the Cardiology Registry.



Cardiology Registry®
is a Veradigm Network solution

© 2023 Veradigm Inc. and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm Inc. and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved. VDMP-516-1 February 2023